Edaravone Dexborneol Attenuates Neuroinflammation by Regulating CXCL13/CXCR5/NF-κB Pathway in MCAO Rats
Donghai Men,Wei Si,Cameron Lenahan,Chengjie Xu,Weichuan Wu,Xiaoyun Liang,Heng Lin,Hao Zhou,Shirong Li,Lu Wang,Xike Wang,Xiangyu Wang,Xiao Hu
DOI: https://doi.org/10.2139/ssrn.4352852
2023-01-01
Abstract:Background: Stroke is a condition of the brain with the highest rates of disability and mortality, and urgently needs more effective treatment options. Edaravone dexborneol is a novel neuroprotective agent compared with Edaravone alone, and it was safe and well-tolerated in treating patients with acute ischemic stroke (AIS). Some studies showed that Edaravone reduced the expression of CXC chemokine 13 (CXCL13) after brain injury. However, the manner in which Edaravone dexborneol played an anti-neuroinflammatory role via regulation of CXCL13 and its downstream signaling pathway has not been elucidated.Methods: Sixty neonatal Sprague-Dawley rats and one hundred and fourty-eight Sprague-Dawley adult rats were used. The experiment was divided into two parts: in vivo and in vitro. Firstly, primary microglia underwent hypoxia-glucose deprivation and reoxygenation (OGD/R) to verify the neuroprotective effect of Edaravone dexborneol on regulating polarization and injury of microglia. Flow cytometry, western blot, immunofluorescence staining, as well as LDH and CCK8 assays were performed. Subsequently, the animal model of AIS was induced via middle cerebral artery occlusion (MCAO). Edaravone dexborneol was administered by tail vein injection at 1 h after MCAO induction. To elucidate the signaling pathway involved in the effect of Edaravone dexborneol on neuroinflammation, recombinant human CXCL13 was administered intracerebroventricularly at 1 h before MCAO. Cerebral infarct area, brain water content, short-term and long-term neurobehavioral tests, western blot, immunofluorescence staining, and Fluoro-Jade C staining were performed.Results: Edaravone dexborneol downgraded the apoptosis and trauma of OGD/R-induced microglia, improved cell viability, modulated microglia M1/M2 polarization, alleviated expression of proinflammatory factors (IL-1β and TNF-α), and promoted the expression of anti-inflammatory factor (IL-4). The in vivo experiment revealed that the expressions of endogenous CXCL13, CXCR5, and p-NF-κB were gradually increased after MCAO, and peaked at 24 h. Edaravone dexborneol significantly improved the short-term neurological deficits at 24 h after MCAO, which was accompanied by alleviating cerebral infarct area, brain edema, and CXCR5 expression on microglia. Edaravone dexborneol also ameliorated long-term neurological deficits at 28 d after MCAO and suppressed the degeneration of hippocampal neurons. Meanwhile, Edaravone dexborneol significantly decreased the expressions of CXCL13, CXCR5, p-NF-κB, IL-1β, and TNF-α, as well as the activation of neutrophil infiltration. Recombinant human CXCL13 abolished these neuroprotective effects of Edaravone dexborneol after MCAO.Conclusions: Our results demonstrate that Edaravone dexborneol regulated the polarization of microglia, attenuated neuroinflammation, and ameliorated neurological deficits in OGD/R-induced microglia and MCAO animal models, possibly by inhibiting CXCL13/CXCR5/NF-κB signaling pathway. These results may help develop new clinical strategies for AIS treatment.